Glycine for Schizophrenia

Verdict: Refuted by larger trials; not effective

For schizophrenia, glycine does not work: early small trials suggested it eased negative symptoms, but the largest, highest-quality trial found no benefit, and added to clozapine it can make positive symptoms worse.

C 🟠 C Weak Evidence Counter-Evidence

🔬Why this grade7-layer evidence engine

Early enthusiasm came from very small crossover RCTs. A 1999 trial (PMID 9892253, n=22) reported a roughly 30% drop in PANSS negative symptoms with high-dose glycine (0.8 g/kg/day) added to standard antipsychotics, with response strongest in patients who started with low serum glycine. But with only ~22 patients, these findings were preliminary and not generalizable.

Larger, better-designed studies overturned this. The NIMH-funded multisite CONSIST trial (PMID 17898352, n=157, 16 weeks) was the highest-quality study and found no benefit of glycine over placebo on negative symptoms or cognition. A pooled meta-analysis of NMDA modulators (PMID 21936588, n=1,253) showed only a small overall effect, and importantly glycine added to clozapine worsened positive symptoms (SMD +0.56). Trials adding glycine to clozapine (PMID 10784481), a later pilot (PMID 30633660), and a GlyT1-inhibitor study (PMID 37141764) were all negative.

Authorities do not support glycine for schizophrenia. The FDA treats it only as a food additive/excipient (it is no longer 'generally recognized as safe' in human food), and EFSA found 'a cause and effect relationship has not been established' for amino-acid health claims. Cleveland Clinic does not mention glycine in its schizophrenia guidance; Harvard's McLean acknowledges the glycine-site target only as a research hypothesis, not a clinical recommendation. This earns a weak/counter-evidence grade: an early positive signal refuted by larger trials, with a real safety concern when combined with clozapine.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.47
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Counter-Evidence
Confidence
79%
Broadly consistent
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.30
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.55
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.465
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
PMID: 9892253 1999 RCT (double-blind) n = 22
Finding: Glycine produced 30%+/-16% reduction in PANSS negative symptoms (p<0.001) and 30%+/-18% improvement in BPRS total (p<0.001); low baseline serum glycine predicted response (r=0.80)
Government Effect size: [object Object]
View on PubMed
Placebo-controlled trial of glycine added to clozapine in schizophrenia
PMID: 10784481 2000 RCT (double-blind) n = 30
Finding: No significant improvement in positive, negative or cognitive symptoms when glycine added to clozapine; authors concluded glycine-site agonists may be less effective with clozapine than with conventional antipsychotics
Academic
View on PubMed
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments
PMID: 17898352 2007 RCT (double-blind) n = 157
Finding: NULL: no significant difference in SANS change between glycine vs placebo or D-cycloserine vs placebo; no cognitive benefit; concluded neither agent is a generally effective therapeutic option for negative symptoms or cognition
🟢 High quality Government
View on PubMed
Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia
PMID: 21936588 2011 統合分析 n = 1,253
Finding: Pooled NMDA modulators: small effect on negative symptoms (SMD -0.27) and medium on total (SMD -0.40); glycine adjunct to non-clozapine showed medium effect on total (SMD -0.66) but worsened positive symptoms when added to clozapine (SMD +0.56); D-serine and sarcosine had broader benefit than glycine
Effect size: [object Object]
View on PubMed
A Pilot Randomized, Placebo-Controlled Trial of Glycine for Treatment of Schizophrenia and Alcohol Dependence
PMID: 30633660 2019 RCT (double-blind) n = 20
Finding: NULL: glycine showed no statistically significant advantage over placebo on heavy drinking, cravings, negative schizophrenia symptoms, or cognition; consistent with larger glycine trials
🟠 Limited quality Government
View on PubMed
Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia
PMID: 37141764 2023 RCT (double-blind) n = 71
Finding: Drug + cognitive training did NOT produce greater improvement in cognition vs cognitive training alone; safe and well-tolerated but failed primary efficacy; indirect glycine-site augmentation also unsuccessful
Government
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
the Food and Drug Administration no longer regards glycine and its salts as generally recognized as safe for use in human food and all outstanding letters expressing sanction for such use are rescinded. source↗
L4b EU EFSA
Against
a cause and effect relationship has not been established source↗
L4d TW TFDA / 衛福部
Neutral
胺基乙酸 Glycine:類別 (十一) 調味劑;使用食品範圍及限量:本品可於各類食品中視實際需要適量使用;使用限制:限於食品製造或加工必須時使用。 source↗
L5d Harvard Health
Neutral
Placebo controlled clinical trials with agents that directly or indirectly activate the glycine modulatory site consistently reduce negative symptoms and frequently improve cognition in patients with chronic schizophrenia who are receiving concurrent typical antipsychotics. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬6 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-schizophrenia-INT-glycine-001 繁體中文版 →